NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $40.00 price target on the stock.

NRXP has been the subject of several other research reports. Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, December 2nd. Finally, BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a report on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP opened at $1.98 on Tuesday. NRx Pharmaceuticals has a 12 month low of $1.17 and a 12 month high of $6.01. The stock has a market cap of $55.64 million, a price-to-earnings ratio of -0.84 and a beta of 1.91. The stock’s 50 day moving average price is $2.68 and its 200 day moving average price is $2.87.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $6.83 million. On average, sell-side analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the third quarter valued at approximately $39,000. One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the period. Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the period. Geode Capital Management LLC lifted its holdings in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the period. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.